%D8%A5%D9%8A%D8%A8%D9%88%D8%AC%D8%A7%D9%8A%D9%8A%D9%86IbogaineIbogainIbogainIbogaineIboga%C3%ADna%D8%A7%DB%8C%D8%A8%D9%88%DA%AF%DB%8C%D9%86IbogaiiniIboga%C3%AFne%D7%90%D7%99%D7%91%D7%95%D7%92%D7%90%D7%99%D7%9FIbogainIbogainIbogaina%E3%82%A4%E3%83%9C%E3%82%AC%E3%82%A4%E3%83%B3Iboga%C4%ABnsIboga%C3%AFneIbogainIbogainaIboga%C3%ADnaIbogain%C4%83%D0%98%D0%B1%D0%BE%D0%B3%D0%B0%D0%B8%D0%BDIbogainIbogainIbogain%D0%86%D0%B1%D0%BE%D0%B3%D0%B0%D1%97%D0%BDQ409455
about
The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complexIbogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review.Ibogaine and addiction in the animal model, a systematic review and meta-analysis.Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.DARK Classics in Chemical Neuroscience: IbogaineIbogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic CircuitsMorphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor LigandsStructurally modified ibogaine analogs exhibit differing affinities for NMDA receptorsIdentification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotoninIbogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac DysrhythmiasBiosynthesis of an Anti-Addiction Agent from the Iboga PlantIbogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use DisorderA case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorderIbogaine as a treatment for substance misuse: Potential benefits and practical dangers
P921
Q28287426-500A5E35-666C-4511-AA1C-8169400C734BQ37225016-2EB3AFBB-1BE4-41D3-80F0-81FF3883A154Q38849032-e9defb23-4900-828e-6a52-22edd5880abcQ48573474-1A8D6665-593F-4F27-9146-68E0645AED6DQ57287028-24303951-824B-4CDE-A1DF-4A3759311CC1Q64062626-2D5933B7-2F98-4C79-AA74-D30FC74770B6Q64273620-CCEE1446-F14D-45FD-AF19-A3290F6BD482Q71692316-231BFB41-DFF9-4E36-9778-F2D484F8F2C4Q71834150-1A5E5DE4-F4C7-44FC-BD03-2DEA0BDCB637Q90828247-3ADFF949-DCDC-44D9-B97B-5E8C3414785BQ92307708-87FADD76-BEC2-4B6C-AB99-B0BBFD3D5249Q92983696-10723B5D-122A-47C2-9E9B-CB8463EF4C17Q93341538-340398D4-93CE-46AC-AC73-B119A2BC171DQ93341552-EDD6D777-2C97-40B5-B15E-396D2308323F
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ibogaiini
@fi
Ibogain
@cs
Ibogain
@de
Ibogain
@hr
Ibogain
@hu
Ibogain
@nb
Ibogain
@sh
Ibogain
@sr-el
Ibogain
@sv
Ibogaină
@ro
type
label
Ibogaiini
@fi
Ibogain
@cs
Ibogain
@de
Ibogain
@hr
Ibogain
@hu
Ibogain
@nb
Ibogain
@sh
Ibogain
@sr-el
Ibogain
@sv
Ibogaină
@ro
altLabel
12-Methoxyibogamine
@en
12-Methoxyibogamine
@fr
83-74-9
@fr
C20H26N2O
@fr
C20H26N2O
@it
C20H26N2O
@sr
Ibogaina
@es
Ibogaine
@fr
Ibogaine
@nl
Tabernanthe iboga
@nl
prefLabel
Ibogaiini
@fi
Ibogain
@cs
Ibogain
@de
Ibogain
@hr
Ibogain
@hu
Ibogain
@nb
Ibogain
@sh
Ibogain
@sr-el
Ibogain
@sv
Ibogaină
@ro